Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients

BACKGROUND: Many immune checkpoint inhibitors (ICIs) have been approved in China to treat non‐small cell lung cancer (NSCLC). However, in the long term, less than 20% of patients benefit from ICIs. To maximize the benefit for NSCLC patients, it is necessary to guide the choice of immunotherapy throu...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Yang, Dongliang, Wang, Hanping, Cui, Xiaoxia, Si, Xiaoyan, Zhang, Xiaotong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262920/
https://www.ncbi.nlm.nih.gov/pubmed/32329229
http://dx.doi.org/10.1111/1759-7714.13442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262920/
https://www.ncbi.nlm.nih.gov/pubmed/32329229
http://dx.doi.org/10.1111/1759-7714.13442

Ejemplares similares